With AML 1b results imminent just a reminder to holders of where we were (are).
The standard of care (chemo) baseline efficiency on AML is approximately 20%.
Ptx-200 monotherapy 1a results were equal to baseline efficiency(slightly higher of memory).
So, if . As a combined therapy, ptx-200 and chemo synergies (correlation variance offset null), then indeed a combined weapon.
AML, as kates has implied on previous post, has eluded more so modern scientific research than most other cancers.
Modestly excited, let the results speak in volumes.
Luck to holders.
PTX Price at posting:
10.5¢ Sentiment: Hold Disclosure: Held
